NEW TRIAL SIZE PRICING
$99 | Effective March 5

Guarantee Statement

Bethyl's purpose is to improve lives by supporting scientific discovery. This drives our complete dedication to the highest standards of product and service quality.

Bethyl is unique in our end-to-end control of the entire antibody lifecycle. From our veterinary facilities to the development, production and validation labs, the Bethyl team focuses on delivering quality products. This attention to quality at every step and the integration across each stage of the process means scientists can rely on Bethyl antibodies. We also offer expert technical support to help ensure your success.

Recognizing that your research and time are valuable, we promise to stand behind our products. Should one of our antibodies fail to return satisfactory results when used in the species, application and under the same conditions stated on the product datasheet, Bethyl will offer a full product replacement, credit or refund at the investigator's discretion. Before providing product replacement, credit or refund, we ask the investigator to complete an application specific questionnaire and work with our Technical Support team to identify potential steps to optimize conditions.

Every Bethyl product ships with a 100% guarantee; choose Bethyl antibodies with confidence.

Product Validation

Valid antibodies, used in the correct context, are specific, selective, and reproducible.


• Specific: Binding is restricted to the target
• Selective: Binding favors the target
• Reproducible: Performance is repeatable

Bethyl’s Approach

Step 1) Antigen Design

The validation of our antibodies begins with antigen design:

1. Two to four peptides to distinct regions of the target protein are chosen.

2. Rabbits are immunized.

3. Antibodies are antigen-affinity purified.

  • Valid antibodies against distinct epitopes will agree in their recognition of a target protein.


  • Step 2) Validation for Specificity and Selectivity in Multiple Applications

    Western blot (WB) and Immunoprecipitation (IP)

    WB is used in conjunction with IP to evaluate specificity and selectivity:


    1. Endogenous target protein is immunoprecipitated with two or more antibodies raised against distinct epitopes.

    2. Immunoprecipitates are immunoblotted with each of the epitope-distinct antibodies.

  • Valid antibodies will recognize the immunoprecipitated protein of an antibody raised against a distinct epitope.

  • WB of IPs, in conjunction with WB of whole cell lysate, allows for the verification of the mobility of the target protein.

  • Western blots using multiple dilutions and a broad spectrum of whole cell lysates enable Bethyl scientists to verify selective binding as well as the specificity, reproducibility, and sensitivity of the antibody.

  • Bethyl qualifies antibodies exhibiting:

    • Specific or selective recognition of the target protein
    • Acceptable sensitivity
    • Reproducibility

    Immunohistochemistry (IHC)

    For the evaluation of antibodies in IHC, multiple antibodies generated against distinct epitopes are used to demonstrate concordance:

  • Valid antibodies generated against distinct epitopes will demonstrate similar staining patterns across a range of tissues and cells.

  • Bethyl’s method for evaluating selectivity in IHC:


    1. Two or more antibodies against distinct epitopes are used to stain a broad spectrum of FFPE tissues and cells.

    2. When selectivity is established, Bethyl scientists find the optimal conditions and dilutions for reproducible immunostaining.

    3. Alternately if more than one antibody exhibiting utility in IHC is not available, the scientific team confirms that the observed staining pattern is in agreement with published studies and curated data.

    Bethyl qualifies antibodies for the application of IHC exhibiting:

  • Expected staining patterns
  • Concordant staining
  • Sensitivity
  • Selectivity
  • Reproducibility

  • Bethyl's validation process is continuous and lot-to-lot consistency is important. New lots are routinely evaluated in side-by-side comparisons with previous lots to assess lot-to-lot consistency. Each new lot must perform similarly to the previous lots in order to be released to market.

    Interested in learning more about Bethyl’s validation process? Read the Application Note published in BioTechniques by clicking here.